Goldman Sachs Downgrades Teva Pharma (TEVA) to Neutral

Goldman Sachs downgraded Teva Pharma (NYSE: TEVA) from Buy to Neutral with a price target of $60.00 (from $70.00).

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $54.98 yesterday.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• Teva Pharma (TEVA) and Teva (TEVA) Announce FDA Approval of SELARSDI
• MFE-MediaForEurope NV (MFEB:IM) PT Raised to EUR3.60 at Barclays